Investor profile
BioMedPartners has backed 11 European tech companies across 15 funding rounds between 2011 and 2024, joining rounds totalling €430M. Most active in Healthtech. Data as of 6 Aug 2026.
Also recorded as: BioMed Partners
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Immunos Therapeutics | Switzerland | 3 | €92M |
| Precirix | Belgium | 1 | €80M |
| Tubulis Technologies | Germany | 2 | €71M |
| Cardior Pharmaceuticals | Germany | 1 | €64M |
| Topas Therapeutics |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Precirix | Series B | €80M | 2022-03 |
| Immunos Therapeutics | Series B | €68M | 2022-06 |
| Cardior Pharmaceuticals | Series B | €64M | 2021-08 |
| Tubulis Technologies |
| Germany |
| 2 |
| €40M |
| Scenic Biotech | Netherlands | 1 | €28M |
| GenKyoTex | Switzerland | 1 | €17M |
| Anergis | Switzerland | 1 | €14M |
| Alentis Therapeutics | Switzerland | 1 | €11M |
| Sequana Medical | Switzerland | 1 | €8.3M |
| Miracor Medical Systems | Austria | 1 | €4.5M |
| Series B |
| €60M |
| 2022-05 |
| Scenic Biotech | Series A | €28M | 2022-03 |
| Topas Therapeutics | Series B | €22M | 2020-10 |
| Topas Therapeutics | Series B | €18M | 2021-07 |
| GenKyoTex | Series D+ | €17M | 2015-01 |
| Anergis | Series A | €14M | 2011-03 |
| Immunos Therapeutics | Series A | €14M | 2019-10 |
